Landiolol for rate control in decompensated heart failure due to atrial fibrillation: the LARISA trial
Marek Sramko, Ales Benak, Jakub Toman, Martin Kleissner, Michal Pazdernik, Josef Kautzner · 2026
Read Landiolol for rate control in decompensated heart failure due to atrial fibrillation: the LARISA trial by Marek Sramko, Ales Benak, Jakub Toman, Martin Kleissner, Michal Pazdernik, Josef Kautzner (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13525480.txt.
Description
Sramko and colleagues trial an intensive heart-rate strategy for a dangerous rhythm problem in failing hearts. Their 2026 LARISA trial enrols 40 patients with acute heart failure caused by atrial fibrillation, with heart rates above 130 and weakened pumping function. One group received protocolised rate control with landiolol, a fast, short-acting intravenous drug, plus digoxin; the other received standard therapy.
Rate control came faster with the intensive approach, at a median of one and a half hours against four hours. By two hours, heart rate had fallen 40 percent in the intensive group against 23 percent with standard care. The target was reached in 80 percent of intensive patients versus 20 percent of the rest. Breathlessness and lung congestion also eased more, without extra low blood pressure or adverse events. By 24 hours the groups had converged, so the benefit is speed.
Catalog record
| CREATOR | Marek Sramko, Ales Benak, Jakub Toman, Martin Kleissner, Michal Pazdernik, Josef Kautzner |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |